Form 6-K IMMUTEP Ltd For: Jul 06

July 7, 2022 6:03 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.





Washington, D.C. 20549







PURSUANT TO RULE 13a-16 OR 15d-16


Dated July 6, 2022

Commission File Number 001-35428




(Exact Name as Specified in its Charter)




(Translation of Registrant’s Name)

Level 33, Australia Square

264 George Street, Sydney

NSW 2000, Australia



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If “Yes” is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 6, 2022



/s/ Marc Voigt

Name:   Marc Voigt
Title:   Chief Executive Officer



ASX/Media Release



SYDNEY, AUSTRALIA – 6 July 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 7074341) entitled “Anti-LAG-3 Antibodies” by the Japanese Patent Office.

This new Japanese patent follows the grant of the equivalent European patent announced in October 2020. The claims of the patent are directed to Immutep’s pre-clinical product candidate IMP761, pharmaceutical compositions comprising IMP761, and the use of the compositions in the treatment of T-cell mediated inflammatory and autoimmune diseases. The expiry date of the patent is 1 September 2036.

Immutep CEO, Marc Voigt stated: “We continue to take important steps to protect our pre-clinical candidate IMP761, which is the first product candidate to act as a LAG-3 agonist, a novel mechanism of drug action that we believe can act directly to treat the root cause of autoimmune diseases. Of course, the LAG-3 immune control mechanism has attracted a great deal of attention in recent months because of the approval by the FDA of the first LAG-3 related product in immuno-oncology. With deep expertise in LAG-3 biology, four LAG-3 product candidates in development, and a comprehensive patent estate, Immutep is well placed to make important contributions to this rapidly emerging field of immunotherapy - in both cancer and autoimmune diseases.”

Immutep CSO and CMO, Dr. Frederic Triebel also stated: “We have been making good progress in advancing IMP761 towards clinical testing and, in recent months, have been working closely with Northway Biotech to develop a GMP compliant manufacturing process using the cell line developed by Batavia BioSciences. It is also good to see continued progress in building our patent estate around this innovative LAG-3 candidate.”

About IMP761

IMP761 is a first-in-class immunosuppressive agonist antibody to LAG-3. As a targeted immunosuppressive antibody, IMP761 has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at the disease site and which express LAG-3 as an “exhaustion marker” after being repeatedly stimulated with dominant self-peptides.

In early 2019, Immutep reported encouraging pre-clinical results from its studies with IMP761. The in vivo studies showed that IMP761 decreases inflammatory T cell infiltration induced by intra-dermal injection of an antigen. These findings were published in the Journal of Immunology in January 2020. Additional pre-clinical research findings from a juvenile arthritis ex vivo model were published in Pediatric Research in May 2021. In these studies, IMP761 was shown to decrease effector T cell cytokine secretion.

Immutep Limited, Level 33, Australia Square

264 George Street, Sydney NSW 2000

ABN: 90 009 237 889



In December 2021, Immutep announced that it had appointed Northway Biotech to develop a GMP compliant manufacturing process and to manufacture IMP761 in large scale bioreactors, ahead of the commencement of clinical testing of the candidate in autoimmune diseases. The process will use a pharmaceutical-grade, stable CHO cell line developed by Batavia Biosciences that has been shown to produce high product yields in a small-scale setup.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268; [email protected]

U.S. Media:

Tim McCarthy, LifeSci Advisors

+1 (212) 915.2564; [email protected]

This announcement was authorised for release by the Board of Immutep Limited.

Immutep Limited, Level 33, Australia Square

264 George Street, Sydney NSW 2000

ABN: 90 009 237 889

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

SEC Filings